Ondansetron Orifarm

Ondansetron, the active ingredient in Ondansetron Orifarm, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Orifarm is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control nausea and vomiting caused by cancer chemotherapy. - Radiation‑induced nausea and vomiting: reduces nausea and vomiting associated with radiation therapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgery. - Hyper‑mutagen ​